



Heart Damage in Rheumatoid Arthritis, What Do We Know? A Case Report

A. Chachi¹*, A. Akrim¹, S. Jourani¹, M. Eljamili¹, S. Elkarimi¹, D. Benzarouel¹, M. Elhattaoui¹

¹Cardiology Department, MOHAMMED VI University hospital, Marrakech, Morocco

| Received: 26.12.2021 | Accepted: 01.02.2022 | Published: 28.02.2022

*Corresponding author: A. Chachi

Cardiology Department, MOHAMMED VI University hospital, Marrakech, Morocco

Abstract

Case Report

Data from population- and clinic-based epidemiologic studies of rheumatoid arthritis patients suggest that individuals with rheumatoid arthritis are at risk for developing clinically evident congestive heart failure. Many established risk factors for congestive heart failure are over-represented in rheumatoid arthritis and likely account for some of the increased risk observed. At present, however, the direct effects of inflammatory cytokines (and rheumatoid arthritis therapies) on the myocardia of rheumatoid arthritis patients are incompletely understood. We report a case of RA first diagnosed after an episode of congestive heart failure (CHF) with total recovery of left ventricular function after immunosuppressive drugs administration.

Keywords: rheumatoid arthritis, heart failure, total recovery.

Copyright © 2022 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

Cardiovascular features in rheumatoid arthritis (RA) are common. Among those are the classical extra-articular features that not only include pericarditis, cardiomyopathy/myocarditis, cardiac amyloidosis, coronary vasculitis, arrhythmia and valve diseases, but also congestive heart failure and ischaemic heart disease which are found more frequently and are associated with an increased mortality compared with the general population. There is a general consensus that a 1.5 multiplication factor is used when using unadapted cardiovascular disease (CVD) predictor algorithms in patients with RA [1]. This increased risk is independent of traditional risk factors such as age, smoking, gender, hypertension, and hyperlipidemia.

Several drugs are used in RA, including corticosteroids, immunosuppressive agents, and biological therapy. They have an important positive effect in the reduction of arthritis activity and improvement of functional capacity, but can also be incriminated in possible deleterious effects on heart function.

We report a case of RA first diagnosed after an episode of congestive heart failure (CHF) and the

evolution of left ventricular function after conventional treatment of CHF and immunosuppressive drugs.

CASE REPORT

The patient, a 52 year old man, with history of epilepsy and non-documented stroke 6 years before, presented to the emergency department with increasing dyspnea. He had had stable dyspnea on exertion of 1 city block for 1 year but never received any medical care. Three weeks prior to admission, the patient had developed dyspnea at rest and orthopnea. In addition, he had experienced polyarthralgia for 2 months. He denied having any episode of chest pain, fever, cough, sore throat, myalgias, headaches or rhinorrhea.

The patient was in moderate distress from dyspnea. However, he was afebrile and had an oxygen saturation of 92% on room air and 97% on 4 liters by nasal cannula. He was slightly tachypneic with a respiratory rate of 20 breaths/minute, and his heart rate was 100 beats/minute and regular. The initial blood pressure was 126/62 mm Hg. The peripheral pulses in the upper and lower extremities were strong and symmetric. On cardiac examination, the patient had no murmurs, rubs, or other adventitious sounds. Lung auscultation revealed rales throughout the lung fields, most evident at the bases. There was no hepatic

engorgement and no splenomegaly. The lower extremities had mild pitting edema. The musculoskeletal examination revealed synovial thickening of the metacarpophalangeal and proximal interphalangeal joints, but there was no joint tenderness.

Results of the initial laboratory workup are shown in Table 1. The patient's alanine aminotransferase, troponin levels and CRP were slightly elevated. His renal function was preserved. An

electrocardiogram (EKG) revealed normal sinus rhythm (75 beats/minute). There were no ST segment or T wave abnormalities, and no sign of left ventricular hypertrophy (Figure 1). A chest radiograph revealed cardiomegaly and Kerley B lines (Figure 2).

An echocardiogram performed in the emergency department showed a global hypokinetic dilated cardiomyopathy with an ejection fraction of 15–20%, with apical thrombus (figure 3).

Table-1: Results of laboratory tests

Hb	13,5 g/dl
White cells count	17960
Neutrophils	
Lymphocytes	
Eosinophils	
Urea	0,7 g/l
Creatinine	11 mg/l
ASAT	154 UI/l
ALAT	74 UI/l
CRP	230
LDL	1,28
Troponin hs	139 -> 141 ug/l (after one hour)
Hemocultures	3 negatives



Fig-2: Chest X-RAY

Initial management

The patient was diagnosed with exacerbation of congestive heart failure (CHF) and was treated with intravenous diuretics. This led to symptomatic improvement. He was in stable condition after 2 days in intensive care units and was put under conventional heart failure treatment: spironolactone 50mg/day Ivabradine 2,5 mg/day, Ramipril 2,5 mg/day and was anticoagulated with vit K antagonists (acenocoumarol).

Etiologic investigations

Several investigations were performed in order to diagnose the etiology the patient's hypokinetic dilated cardiomyopathy. Regarding his gender, history of stroke and LDL levels, a coronarography was first performed and returned normal (figure 4).

Biological tests were carried out in search of metabolic, immunological and viral abnormalities. Viral serologies were negative. The martial, phosphocalcic and thyroid markers were normal. However, the immunologic tests showed positive rheumatoid factor and anti-CCP. Anti-DNA, anti-ENA, anti-SSA, anti-SSB, Anti-phospholipids, anti-b2-glycoprotein, and ANCA were all negative (table 2).

Final diagnosis

The diagnosis of dilated cardiomyopathy due to rheumatoid arthritis was retained. The patient was transferred to internal medicine department where he was put under corticosteroids (3 intravenous bolus of 1g solumedrol, with oral relay) and immunosuppressive agents (cyclophosphamide 1g/ month during 6 months)

Follow-up

Patient was seen during routine follow-up after 6 months. Interestingly, echocardiographic findings were totally normal with left ventricular ejection fraction >50% and normal LV size (figure 5).

DISCUSSION

In more recent publications, pericarditis is still encountered as the most frequent finding in

echocardiographic series, with incidences ranging between 30% and 50% [2]. In contrast, the epidemiology of RA associated cardiomyopathy/myocarditis is less well explored. A study reported that 7 (25%) of 28 patients with RA had increased myocardial uptake in gallium scintigraphy, possibly consistent with myocardial inflammation [3]. In a recent autopsy study of 81 patients with RA who died in the hospital, 13 (16%) died of heart failure, whereas in the age- and sex-matched control group of 243 non-RA patients, only 8 (3%) patients died of heart failure. Variable changes were noted in patients with RA carrying the diagnosis of heart disease prior to death, including pericarditis, myocarditis, angiitis, microinfarcts, granulomatous lesions, and amyloid deposits [4].

Patients with RA seem to have not only the CHF risk associated with IHD and traditional cardiovascular risk factors that is observed in the general population, but also an additional risk apparently not associated with traditional cardiovascular risk factors or clinically overt IHD, which contributes to their excess mortality. Several possible etiologic mechanisms involved in the increased risk of CHF in patients with RA have been described. Results of recent studies suggest that in the elderly population, higher levels of systemic markers of inflammation predict the risk of CHF [5].

Even in the absence of MI [6]. Other possible explanations include a higher prevalence of unrecognized or subclinical IHD and/or cardiovascular risk factors that could, at least partially, promote CHF. Pericardial and valvular disease, which are possible complications of RA [7], and the potential cardiotoxic effect of RA drugs such as nonsteroidal anti-inflammatory drugs [8], corticosteroids, chloroquine [9], D-penicillamine [10], or biologic agents (especially tumor necrosis factor inhibitors) may also play a role.

In our case report, HF conventional treatment associated with glucocorticosteroids and cyclophosphamide led to total regaining of LV ejection fraction (15 % → >50%). However, data in literature is more nuanced.

The treatment of HF in patients with RA is similar to that in those without RA. In terms of RA therapy, paradoxically, medications used in the treatment of RA may also contribute to HF.

NSAIDs — Nonselective NSAID use is not associated with a first occurrence of heart failure (HF); however, it can cause a worsening of preexisting HF. The major mechanism for HF exacerbation is an increase in afterload resulting from NSAID-induced systemic vasoconstriction, which can lead to a further reduction in cardiac contractility and cardiac output in advanced HF. Data are more limited but there is a

similar concern with the COX-2 selective agents. Several studies have presented data indicating that the selective COX-2 inhibitor, celecoxib, may have an improved cardiorenal safety profile compared with ibuprofen or diclofenac (nonselective NSAIDs) [12].

Glucocorticoids — Therapeutic use of glucocorticoids has been associated with dose-dependent increased rates of heart failure, myocardial infarction, stroke, and all-cause mortality [13]. In a large observational study, the risk of heart failure appeared to increase with the daily dose of glucocorticoids prescribed, with a rate ratio of 3.72 (95% CI 2.71-5.12) with greater than or equal to 7.5 mg/day of prednisone or its equivalent compared with nonusers [14]. The cardiovascular risk was higher for those who had continuing prescriptions than for intermittent prescribing of glucocorticoids and higher for those using glucocorticoids during the six months prior to the cardiovascular event versus at an earlier time.

Targeted TNF-alpha inhibitor use may be associated with heart failure (HF). Concern about this possible adverse effect stems from randomized clinical trials of TNF-alpha inhibitors as a potential therapy for HF, and from postmarketing surveillance data gathered by the FDA. Clinical trials of both etanercept and infliximab were performed with the hypothesis that TNF-alpha inhibition would improve cardiac function in patients with HF [15, 16].

Two major randomized, placebo-controlled trials evaluated etanercept as a possible therapy HF: the RENAISSANCE trial and the RECOVER trial [17, 18]. Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction less than 31 percent were enrolled. The two trials differed in the dose of etanercept used. The primary end point in both trials was clinical status at 24 weeks. In addition, analysis of the effect of the two higher doses of etanercept on the combined outcome of death or hospitalization due to chronic HF from the two studies was also planned.

In the combined analysis of these two trials (ie, RENEWAL), etanercept was found to have no effect on the death or chronic HF hospitalization end point. The relative risk for etanercept-treated patients was 1.1 (95% CI 0.9-1.3). On the basis of prespecified stopping rules, both trials were terminated prematurely because of futility. In addition to excluding any clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic HF, RENEWAL also raised concerns about the possible exacerbation of HF in some patients treated with TNF-alpha inhibitors.

These concerns were confirmed in a trial involving infliximab as a therapy for HF, known as the

ATTACH trial [15]. In this trial, the major inclusion criteria were New York Heart Association class III or IV HF and a left ventricular ejection fraction less than 35 percent. One hundred and fifty patients were divided into three treatment groups: placebo, infliximab 5 mg/kg, and infliximab 10 mg/kg. Infliximab was administered by intravenous infusion at weeks 0, 2 and 6. No infliximab was given after week six, and patients were followed for one year.

An analysis of all-cause mortality at one year showed that deaths were highest in the high-dose infliximab arm. There were eight deaths (16 percent) in the infliximab 10 mg/kg group, compared with four (8 percent) in both the infliximab 5 mg/kg and placebo groups.

Given the evidence to date, in patients with symptomatic HF, it is suggested that treatment strategies other than TNF-alpha inhibitors should be employed. In a patient who develops HF while on a TNF-alpha inhibitor, a drug-induced cause should be suspected and use of the medication should be suspended.

For patients with RA and mild (NYHA functional class I or II) HF whose arthritis is refractory to other DMARDs or biologic agents, targeted TNF-alpha inhibition might be considered.

Cyclophosphamide is related to many adverse reactions such as marrow suppression, susceptibility to infections, sterility and amenorrhea, as well as nephrotoxicity and cystitis, and most importantly cardiovascular complications, for instance, sinus bradycardia, pericarditis, myocarditis and heart failure. More studies need to be conducted in order to determine the eventual indication of cyclophosphamide in patients with heart failure with RA.

CONCLUSION

- The risk of developing heart failure (HF) is increased in patients with RA. The prevalence of echocardiographically determined LV systolic and both left and right ventricular diastolic dysfunction is also increased in this population.
- RA itself appears to be an independent risk factor beside established risk factors (eg, hypertension, diabetes, dyslipidemia)
- The differential diagnosis of HF in patients with RA includes interstitial lung disease and pericardial disorders.
- Antiinflammatory and anti-rheumatic drug therapy may play a role in precipitating or exacerbating HF. These include: anti-TNF agents, NSAIDs, COX-2 selective inhibitors, antimalarial drugs, and glucocorticoids.
- Primary prevention of HF in RA patients is based on modifying traditional risk factors for HF, for

ischemic heart disease, and optimizing control of RA disease activity.

- Echocardiography should be performed in patients with RA who have abnormalities on history, physical examination and/or ECG that are suggestive of LV dysfunction.
- Treatment of HF is similar in patients with and without RA, but attention to the possible adverse cardiovascular effects of antiinflammatory and anti-rheumatic drug therapy may lead to additional diagnostic studies, such as endomyocardial biopsy and/or cessation or gradual withdrawal of certain agents, particularly NSAIDs, COX-2 selective inhibitors, and glucocorticoids.

REFERENCES

1. Agca, R., Heslinga, S. C., Rollefstad, S., Heslinga, M., McInnes, I. B., Peters, M. J. L., ... & Nurmohamed, M. T. (2017). EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Annals of the rheumatic diseases*, 76(1), 17-28.
2. Voskuyl, A. E. (2006). The heart and cardiovascular manifestations in rheumatoid arthritis. *Rheumatology*, 45(suppl_4), iv4-iv7.
3. Hardouin, P., Thévenon, A., Beuscart, R., Tison-Muchery, F., Duquesnoy, B., Théry, C., ... & Delcambre, B. (1988). Evaluation of cardiac involvement in advanced rheumatoid arthritis. Clinical, electrocardiographic, echographic and gallium and thallium double scintigraphic study of 28 patients. *Revue du rhumatisme et des maladies osteo-articulaires*, 55(9), 683-687.
4. Suzuki, A., Ohosone, Y., Obana, M., Mita, S., Matsuoka, Y., Irimajiri, S., & Fukuda, J. (1994). Cause of death in 81 autopsied patients with rheumatoid arthritis. *The Journal of rheumatology*, 21(1), 33-36.
5. Cesari, M., Penninx, B. W., Newman, A. B., Kritchevsky, S. B., Nicklas, B. J., Sutton-Tyrrell, K., ... & Pahor, M. (2003). Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. *Circulation*, 108(19), 2317-2322.
6. Vasan, R. S., Sullivan, L. M., Roubenoff, R., Dinarello, C. A., Harris, T., Benjamin, E. J., ... & D'Agostino, R. B. (2003). Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. *Circulation*, 107(11), 1486-1491.
7. Kitas, G., Banks, M. J., & Bacon, P. A. (2001). Cardiac involvement in rheumatoid disease. *Clinical Medicine*, 1(1), 18.
8. Rodríguez, L. A. G., & Hernández-Díaz, S. (2003). Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. *Epidemiology*, 240-246.

9. Baguet, J. P., Tremel, F., & Fabre, M. (1999). Chloroquine cardiomyopathy with conduction disorders. *Heart*, *81*(2), 221-223.
10. Wright, G. D., Wilson, C., & Bell, A. L. (1994). D-penicillamine induced polymyositis causing complete heart block. *Clinical rheumatology*, *13*(1), 80-82.
11. Mutru, O., Laakso, M., Isomäki, H., & Koota, K. (1989). Cardiovascular mortality in patients with rheumatoid arthritis. *Cardiology*, *76*(1), 71-77.
12. Whelton, A., Lefkowitz, J. L., West, C. R., & Verburg, K. M. (2006). Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. *Kidney international*, *70*(8), 1495-1502.
13. Wei, L., MacDonald, T. M., & Walker, B. R. (2004). Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Annals of internal medicine*, *141*(10), 764-770.
14. Wei, L., MacDonald, T. M., & Walker, B. R. (2004). Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Annals of internal medicine*, *141*(10), 764-770.
15. Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003). Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor- α , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation*, *107*(25), 3133-3140.
16. Kwon, H. J., Cot, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003). Case reports of heart failure after therapy with a tumor necrosis factor antagonist. *Annals of internal medicine*, *138*(10), 807-811.
17. Mann, D. L., McMurray, J. J., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., ... & Fleming, T. (2004). Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation*, *109*(13), 1594-1602.
18. Anker, S. D., & Coats, A. J. (2002). How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. *International journal of cardiology*, *86*(2-3), 123-130.